Biotransformation of Korean Panax ginseng by Pectinex(Miscellaneous)

    • KIM Bo-Hye
    • Department of Microbiology and Immunology, Pusan National University School of Medicine
    • LEE Sun-Yi
    • Department of Microbiology and Immunology, Pusan National University School of Medicine
    • CHO Hyo-Jin
    • Department of Microbiology and Immunology, Pusan National University School of Medicine
    • YOU Sun-Nyoung
    • Department of Microbiology and Immunology, Pusan National University School of Medicine

    • KIM Yeong-Jin
    • Department of Microbiology and Immunology, Pusan National University School of Medicine
    • PARK Yeong-Min
    • Department of Microbiology and Immunology & National Research Laboratory of Dendritic Cell Differentiation and Regulation, Pusan National University College of Medicine
    • LEE Jae-Kwon
    • Department of Food Science and Biotechnology, Kyonggi University
    • BAIK Moo-Yeol
    • Department of Food Science and Technology, Institute of Life Resource Science, Kyunghee University

    • PARK Cheon-Seok
    • Department of Food Science and Technology, Institute of Life Resource Science, Kyunghee University
    • AHN Soon-Cheol
    • Department of Microbiology and Immunology, Pusan National University School of Medicine:Medical Research Institute, Pusan National University Hospital

抄録

Ginsenosides comprise the major component of ginseng exhibit various types of biological activity, including antiinflammatory and antitumor effects. In these pharmacological actions, it is thought that these activities are carried out by the metabolites of ginsenosides metabolized by human intestinal microflora. It has also been reported that their clinical efficacy varies with the hydrolyzing potential of the components of the intestinal microflora. We tried to develop a process for metabolizing ginsenosides to compound K using food-grade enzymes, which can be used commercially. Among these, Pectinex proved to be the most effective mediator of the catabolism of ginsenosides to compound K. The optimal conditions for this biotransformation were determined to be as follows: 10 to 15% rootlet ginseng, pH 5, 50℃, and 2 to 3 d of incubation, to yield 20.0mg of compound K/g of rootlet ginseng. We suggest that the metabolism of ginseng to compound K in the presence of Pectinex has many advantages over previous methods, in respects of use of raw, non-extracted rootlet ginseng, which do not require more organic solvents and evaporation apparatus. Potential metabolites PG1, PG2, PG3, and PG4 were detected in Pectinex-treated rootlet ginseng using by TLC and HPLC and, among them, PG4 was identified as compound K by TLC, HPLC, and MS. Additional studies will be carried out to determine the structure of these metabolites of ginseng and to understand the relationship between their structures and activities.

収録刊行物

Biological & pharmaceutical bulletin   [巻号一覧]

Biological & pharmaceutical bulletin 29(12), 2472-2478, 2006-12-01  [この号の目次]

公益社団法人日本薬学会

参考文献:  20件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

被引用文献:  1件

被引用文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

プレビュー

プレビュー

各種コード

  • NII論文ID(NAID) :
    110006148673
  • NII書誌ID(NCID) :
    AA10885497
  • 本文言語コード :
    ENG
  • 資料種別 :
    ART
  • ISSN :
    09186158
  • NDL 記事登録ID :
    8548940
  • NDL 雑誌分類 :
    ZS51(科学技術--薬学)
  • NDL 請求記号 :
    Z53-V41
  • 収録DB :
    CJP書誌  CJP引用  NDL  NII-ELS  J-STAGE